Survival in a contemporary, real-world, matched cohort of patients with transthyretin amyloid cardiomyopathy treated vs not treated with tafamidis

Back

ESC2025 Premium Access

Survival in a contemporary, real-world, matched cohort of patients with transthyretin amyloid cardiomyopathy treated vs not treated with tafamidis

Session: Prognostication and treatment of transthyretin cardiac amyloidosis

Topic: Infiltrative Myocardial Disease

Speaker: Doctor M. Hanna (Cleveland, US)

Event: ESC Congress 2025

Congress Presentation

Add to my library

About the speaker

Doctor Mazen Hanna

Cleveland Clinic Main Campus, Cleveland (United States of America)

2 presentations

0 follower

7 more presentations in this session

Cardiac resynchronization therapy, remodeling and outcome in patients with amyloid transthyretin cardiomyopathy

Speaker: Doctor A. Aimo (Pisa, IT)

When to stop? Real-world decision pathways for transthyretin stabilizer discontinuation in cardiac amyloidosis

Speaker: Doctor K. Knoll (Munich, DE)

Impaired right ventricular free wall strain predicts mortality in patients with stabilizer-treated transthyretin amyloid cardiomyopathy.

Speaker: Doctor S. Schwarting (Munich, DE)

Distribution and prognostic impact of left and right systolic and diastolic functions in wild-type transthyretin amyloid cardiomyopathy

Speaker: Doctor A. Mejren (Aarhus, DK)

Identifying predictors and cutoff values for pacemaker implantation in ATTR patients

Speaker: Doctor S. Istratoaie (Cluj Napoca, RO)

Access the full session

Prognostication and treatment of transthyretin cardiac amyloidosis

Speakers: Doctor M. Hanna, Doctor A. Aimo, Doctor K. Knoll, Doctor S. Schwarting, Doctor A. Mejren...

Access

About the event

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Explore sponsored resources